New eye drug shows promise in early safety trial for blinding disease
NCT ID NCT05643118
First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug might help improve vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Retina Consultants
Santa Maria, California, 93434, United States
-
Ophthalmic Consultants of the Capital Region
Troy, New York, 12180, United States
-
Texas Retina Consultants
Bellaire, Texas, 77401, United States
-
The Retina Institute
St Louis, Missouri, 63128, United States
-
University Retina
Oak Forest, Illinois, 60452, United States
Conditions
Explore the condition pages connected to this study.